Their findings demonstrated that the mTERT promoter (containing additional Sp1 and c-Myc binding sites) induces a higher level of transgene expression than unmodified human TERT promoter in various TERT-positive cancer cells (up to 10-fold higher gene expression), showing that promoter activity can be improved in cancer through insertion of additional binding sites for oncogenic transcription factors upstream of the promoter. This evidence concerns the gene TERT and cancer.